Impact of molecular profiling on clinical trial design for glioblastoma

被引：6

作者：

Chakravarti A. ^{[1
]}

Tyndall E. ^{[1
]}

Palanichamy K. ^{[1
]}

Mehta M. ^{[1
]}

Aldape K. ^{[1
]}

Loeffler J. ^{[1
]}

机构：

[1] Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA 02114

来源：

Current Oncology Reports | 2007年 / 9卷 / 1期

关键词：

Temozolomide; CCNU; Icatin;

D O I：

10.1007/BF02951429

中图分类号：

学科分类号：

摘要：

This review highlights the ways in which molecular and genetic profiling of malignant gliomas has led to intelligent clinical trial: design. The review also highlights known resistance mechanisms to conventional therapies in malignant gliomas and potential strategies to overcome these mechanisms with the use of targeted therapy. Copyright © 2007 by Current Medicine Group LLC.

引用

页码：71 / 79

页数：8

共 45 条

[21]

Dent P., Reardon D.B., Park J.S., Et al., Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death, Mol Biol Cell, 10, pp. 2493-2506, (1999)

[22]

Barker II F.G., Simmons M.L., Chang S.M., Et al., EGFR overexpression and radiation response in glioblastoma multiforme, Int J Radiat Oncol Biol Phys, 51, pp. 410-418, (2001)

[23]

Shinojima N., Tada K., Shiraishi S., Et al., Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme, Cancer Res, 63, pp. 6962-6970, (2003)

[24]

Chakravarti A., Delaney M.A., Noll E., Et al., Prognostic and pathologic significance of quantitative protein expression profiling in human gliomas, Clin Cancer Res, 7, pp. 2387-2395, (2001)

[25]

Etienne M.-C., Formento J.L., Lebrun-Frenay C., Et al., Epidermal growth factor receptor and labeling index are independent prognostic factors in glial turmor outcome, Clin Cancer Res, 4, pp. 2383-2390, (1998)

[26]

Feldkamp M.M., Lala P., Lau N., Et al., Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens, Neurosurgery, 4 S, pp. 1442-1453, (1999)

[27]

Smith J.S., Tachibana I., Passe S.M., Et al., PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme, J Natl Cancer Inst, 93, pp. 1246-1256, (2001)

[28]

Rainov N.G., Dobberstein K.U., Bahn H., Prognostic factors in malignant glioma: Influence of the overexpression of oncogene and tumor-suppressor gene products on survival, J Neurooncol, 35, pp. 13-28, (1997)

[29]

Chakravarti A., Seiferheld W., Tu X., Et al., Immumohistochemically determined total EGFR levels are not of prognostic value in newly diagnosed GBM: A Report from the Radiation Therapy Oncology Group, Int J Radiat Oncol Biol Phys, 62, pp. 318-327, (2005)

[30]

Buckner J.C., Aldape K.D., Ballman K., Et al., Immunohistochemical detection of EGFRvIII and prognostic significance in patients with malignant glioma enrolled in NCCTG clinical trials, J Clin Oncol, 22, 14 S, (2004)

← 1 2 3 4 5 →